证券代码：603368 证券简称：柳药集团 公告编号：2025-057 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开第 五届董事会第二十七次会议，审议通过了《关于以集中竞价交易方式回购股份方 案的议案》，同意公司使用自有资金和自筹资金通过集中竞价交易方式回购部分公 司 A 股股份，在未来适宜时机用于实施股权激励及/或员工持股计划。本次回购资 金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含）；回购价 格上限不超过人民币 25.70 元/股（含）；回购期限为自董事会审议通过本次回购方 案之日起不超过 12 个月。具体内容详见公司分别于 2025 年 7 月 26 日、2025 年 8 月 5 日在上海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方 式回购股份方案的公告》（公告编号：2025-053）、《关于以集中竞价交易方式回购 股份的回购报告书》（公告编号：2025-056）。 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount ranging from RMB 100 million to RMB 200 million, aimed at implementing equity incentives and/or employee stock ownership plans in the future [1][3][11]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 100 million and not exceed RMB 200 million [1][3]. - The funding sources for the repurchase will be the company's own funds and self-raised funds, with a loan commitment of up to RMB 180 million from a bank [1][10]. - The maximum repurchase price is set at RMB 25.70 per share, which is 150% of the average trading price over the previous 30 trading days [1][9]. Repurchase Execution - The repurchase will be conducted through a centralized bidding method and is expected to be completed within 12 months from the board's approval [2][5]. - The estimated number of shares to be repurchased ranges from approximately 389,110 shares to 778,210 shares, accounting for 0.98% to 1.96% of the total share capital [7][8]. Purpose and Impact - The repurchased shares will be used for equity incentives and/or employee stock ownership plans, enhancing investor confidence and aligning the interests of shareholders and employees [5][11]. - The company believes that the repurchase will not significantly impact its operations, financial status, or future development [11][12]. Shareholder Information - As of the board's approval date, major shareholders, including directors and actual controllers, have no plans to reduce their holdings in the next three to six months [2][13]. - The company has established a dedicated securities account for the repurchase, ensuring compliance with regulations [16].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 2.95% increase in the biopharmaceutical sector while the total A-share market declined by 1.01% [28][4]. - The report highlights significant advancements in Alzheimer's disease treatments presented at the 2025 AAIC conference, with multiple drugs updating their clinical research data [11][5]. - Roche's Trontinemab, a new generation Aβ antibody, demonstrated a 91% clearance rate of Aβ plaques in high-dose groups during Phase 1b/2a trials, indicating promising safety and efficacy [2][12]. Market Performance - The overall A-share market decreased by 1.01%, while the biopharmaceutical sector increased by 2.95%, with chemical pharmaceuticals leading with a 5.01% rise [28][4]. - The current price-to-earnings (P/E) ratio for the pharmaceutical sector is 39.10x, which is at the 80.69th percentile of its historical valuation over the past five years [33][4]. Key Companies and Investment Ratings - Mindray Medical (300760.SZ): Outperform, market cap 275.5 billion, projected net profit for 2024A is 11.67 billion [4]. - WuXi AppTec (603259.SH): Outperform, market cap 267 billion, projected net profit for 2024A is 9.35 billion [4]. - New Industries (300832.SZ): Outperform, market cap 42.6 billion, projected net profit for 2024A is 1.83 billion [4]. - Huatai Medical (688617.SH): Outperform, market cap 39.4 billion, projected net profit for 2024A is 670 million [4]. - Aier Eye Hospital (not listed): Outperform, focusing on rapid expansion in the ophthalmology service sector [37]. Clinical Research Developments - Trontinemab's Phase 1b/2a study showed significant reductions in Aβ plaque levels, with the 3.6 mg/kg dose group achieving a mean reduction from 119 CL to 21 CL after 12 weeks [14][12]. - The report emphasizes the strategic focus of overseas pharmaceutical companies on CNS (central nervous system) drug development, particularly in Alzheimer's treatments [2][25]. Recommendations - The report suggests monitoring the domestic and international AD detection and treatment drug-related industry chain, highlighting the potential for growth in this area [2][25].

Core Viewpoint - Zhejiang Zhenyuan (000705) announced that it will hold the first extraordinary general meeting of shareholders in 2025 on August 20, 2025, to review the proposal for the addition of directors to the 11th Board of Directors [1] Group 1 - The extraordinary general meeting is scheduled for August 20, 2025 [1] - The agenda includes the proposal to supplement the 11th Board of Directors [1]

Group 1 - The company Zhejiang Zhenyuan announced the appointment of Zhou Qiaomi as the new general manager and Zhang Bin as the new financial director, with Zhang Yufeng stepping down from the financial director role [2] - For the fiscal year 2024, the revenue composition of Zhejiang Zhenyuan is projected to be 82.04% from commercial activities and 17.96% from industrial-pharmaceutical manufacturing [2]

（文章来源：每日经济新闻） 浙江震元（SZ 000705，收盘价：9.57元）8月4日晚间发布公告称，公司第十一届2025年第三次董事会 临时会议于2025年8月4日以通讯形式召开。会议审议了《关于增补第十一届董事会董事的议案》等文 件。 2024年1至12月份，浙江震元的营业收入构成为：商业占比82.04%，工业-医药制造占比17.96%。 ...

证券之星消息，8月4日医药商业板块较上一交易日下跌0.23%，塞力医疗领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 目洋医药 | 22.39 | 1.91% | 12.41万 | 2.71亿 | | 603939 | 益丰药房 | 24.60 | 1.61% | 6.75万 | 1.65亿 | | 603233 | 大参林 | 17.58 | 0.92% | 4.67万 | 8141.04万 | | 600511 | 国药股份 | 30.04 | 0.74% | 5.65万 | 1.69亿 | | 603122 | 合富中国 | 7.28 | 0.55% | 6.14万 | 4434.06万 | | 301017 | 漱玉平民 | 13.35 | 0.45% | 6.99万 | 9203.55万 | | 605266 | 健之佳 | 22.0 ...

（文章来源：每日经济新闻） 柳药集团（SH 603368，收盘价：18.54元）8月4日晚间发布公告称，截至2025年7月31日，公司尚未通 过集中竞价交易方式回购公司股份。 2024年1至12月份，柳药集团的营业收入构成为：批发占比78.89%，零售占比15.15%，工业占比 5.49%，其他业务占比0.4%，其他行业占比0.08%。 ...

Group 1 - The core point of the article is that Nanjing Pharmaceutical has repurchased approximately 16.30 million shares, accounting for 1.25% of the total share capital as of July 31, 2025 [2] - The company's revenue composition for the year 2024 is as follows: wholesale accounts for 94.72%, retail for 4.53%, e-commerce for 0.48%, other businesses for 0.24%, and third-party logistics for 0.03% [2]

每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 每经AI快讯，国药股份（SH 600511，最新价：29.71元）7月31日晚间发布公告称，公司第八届第二十 七次董事会会议于2025年7月31日在北京召开。会议审议了《国药股份关于修订 <董事会审计委员会实 施细则> 等部分公司治理制度的议案》等文件。 2024年1至12月份，国药股份的营业收入构成为：医药商业占比104.55%，医药工业占比0.93%，仓储物 流占比0.78%，其他业务占比0.19%，内部抵销占比-6.45%。 （记者 王瀚黎） ...